Valuation
- Market cap
- 6,535,000
- Revenue TTM
- $0
- Net income TTM
- $-8,770,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 72,900
- Avg volume
- 102,830
- Day's range
- $1.46 – $1.53
- Shares out
- 4,476,000
- Stochastic %K
- 35%
- Beta
- 1.18
- Analysts
- Strong Buy
- Price target
- $10.00
Company profile
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indole...
Show more
Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications. The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 444 8400
- Website
- https://www.enveric.com
- Address
- 245 First Street, Riverview II 18 th Floor, Cambridge, United States
Latest news
No headlines yet.
